Small Cell Neuroendocrine Carcinoma — Trials

Small Cell Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,165 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 396
Recruiting: 209
Ph III recruiting: 27
Growth YoY: +1%
Industry share: 42%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (167)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06064500	Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer	approved for marketing	—	—	AmgenINDUSTRY	4	Mar 10, 2025	clinicaltrials
NCT04504513	Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer	approved for marketing	—	—	G1 Therapeutics, Inc.INDUSTRY	0	Mar 19, 2021	clinicaltrials